<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03805477</url>
  </required_header>
  <id_info>
    <org_study_id>2018-00837; me17Hostettler</org_study_id>
    <nct_id>NCT03805477</nct_id>
  </id_info>
  <brief_title>Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell Transplantation</brief_title>
  <acronym>NINBOST2018</acronym>
  <official_title>Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell Transplantation (HSCT)- a Multicentre Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the safety and tolerability of Nintedanib in patients with&#xD;
      bronchiolitis obliterans syndrome (BOS) following allogeneic hematopoietic cell&#xD;
      transplantation. All study patients with BOS will be treated with the study drug Nintedanib&#xD;
      (300 mg/day) as an add-on therapy to their basic immunosuppressive treatment over a 12-months&#xD;
      treatment period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allogeneic hematopoietic stem cell transplantation (HCT) is an established treatment option&#xD;
      for several malignant and non-malignant disorders. An important limitation of long-term&#xD;
      survival after HCT is chronic graft-versus-host disease (cGvHD). The manifestation of cGvHD&#xD;
      in the lungs, bronchiolitis obliterans (BO - if proven by lung biopsy) or bronchiolitis&#xD;
      obliterans syndrome (BOS - clinical diagnosis), has a reported incidence between 5 and 20%.&#xD;
      Despite different treatment approaches, prognosis of BO remains poor, with an overall 3-year&#xD;
      mortality of up to 65%. Nintedanib is an orally available indolinone derivate that&#xD;
      competitively binds to the vascular endothelial growth factor (VEGF) receptors, fibroblast&#xD;
      growth factor (FGF) receptors, and platelet derived growth factor (PDGF) receptors. The&#xD;
      anti-fibrotic activities of Nintedanib may impact the progressive course of fibrotic lung&#xD;
      diseases like BO. This study investigates the safety and tolerability of Nintedanib in&#xD;
      patients with bronchiolitis obliterans syndrome following allogeneic hematopoietic cell&#xD;
      transplantation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 20, 2019</start_date>
  <completion_date type="Anticipated">August 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>adverse event rate leading to interruption/ discontinuation of study treatment</measure>
    <time_frame>from screening to month 12 after screening</time_frame>
    <description>adverse events of the following severity according to Common terminology criteria for adverse events(CTCAE): Diarrhoea ≥ grade 3; Nausea ≥ grade 3; Vomiting ≥ grade 3; Abdominal pain ≥ grade 3; Elevation of liver enzymes (AST, ALT) ≥ grade 2; Elevation of total bilirubin ≥ 2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change of the percent of predicted forced expiratory volume in 1 second (FEV1)</measure>
    <time_frame>Pulmonary function tests will be performed at screening, after 1, 2, 3, 6, 9, 12 and after 13 months</time_frame>
    <description>absolute change of the percent of predicted FEV1 by ≥10% from FEV1 before enrolment (eg, 50% to 40% predicted FEV1), confirmed by 2 pulmonary function tests (PFT) performed at least two weeks apart and after exclusion of infections and extra pulmonary causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in forced vital capacity (FVC)</measure>
    <time_frame>Pulmonary function tests will be performed at screening, after 1, 2, 3, 6, 9, 12 and after 13 months</time_frame>
    <description>volume of air that can forcibly be blown out after full inspiration, (measured in Liters)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in total lung capacity (TLC)</measure>
    <time_frame>Pulmonary function tests will be performed at screening, after 1, 2, 3, 6, 9, 12 and after 13 months</time_frame>
    <description>the volume in the lungs at maximal Inflation (measured in liters)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in diffusion capacity of the lung for carbon monoxide (DLCO)</measure>
    <time_frame>Pulmonary function tests will be performed at screening, after 1, 2, 3, 6, 9, 12 and after 13 months</time_frame>
    <description>extent to which oxygen passes from the air sacs of the lungs into the blood (measured in &quot;ml/min/kPa)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in exhaled nitric oxide (eNO)</measure>
    <time_frame>Pulmonary function tests will be performed at screening, after 1, 2, 3, 6, 9, 12 and after 13 months</time_frame>
    <description>Change in exhaled nitric oxide (eNO) (measured in parts per Billion)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nitrogen (N2)-washout</measure>
    <time_frame>Pulmonary function tests will be performed at screening, after 1, 2, 3, 6, 9, 12 and after 13 months</time_frame>
    <description>The following describes a single-breath nitrogen test: A subject takes a breath of 100% oxygen and exhales through a one-way valve measuring nitrogen content and volume. A plot of the nitrogen concentration (as a % of total gas) vs. expired volume is obtained by increasing the nitrogen concentration from zero to the percentage of nitrogen in the alveoli. The nitrogen concentration is initially zero because the subject is exhaling the dead space oxygen they just breathed in (does not participate in alveolar exchange), and climbs as alveolar air mixes with the dead space air. The dead space can be determined from this curve by drawing a vertical line down the curve such that the areas below the curve (left of the line) and above the curve (right of the line) are equal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in in 6 minutes walking distance (6-MWD)</measure>
    <time_frame>6-MWD will be performed at screening, after 6, after 12 months</time_frame>
    <description>standardized 6-minute walk test will be performed breathing room air and performed according to the guidelines of the American Thoracic Society. Significant drop of transcutaneous measured arterial oxygen Saturation (SaO2) is defined as a ΔSaO2 ≥ 4% or SaO2 &lt; 90%. A significant change in walking distance will be Δ distance = 40 metre.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative steroid doses</measure>
    <time_frame>assessed at screening, after 1, 2, 3, 6, 9, 12, and after 13 months</time_frame>
    <description>steroid doses per month (in mg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>occurrence of GvHD in other organs</measure>
    <time_frame>assessed at screening, after 1, 2, 3, 6, 9, 12, and after 13 months</time_frame>
    <description>occurrence of GvHD in other organs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease-free survival of underlying hematologic disease</measure>
    <time_frame>assessed at screening, after 1, 2, 3, 6, 9, 12, and after 13 months</time_frame>
    <description>disease-free survival of underlying hematologic disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in St. George's Respiratory Questionnaire (SGRQ)</measure>
    <time_frame>assessed at screening, after 1, 2, 3, 6, 9, 12, and after 13 months</time_frame>
    <description>The SGRQ is designed to measure health impairment in patients with asthma and chronic obstructive pulmonary disease (COPD); 3 component scores are calculated: symptoms; activity; impacts. Each questionnaire response has a unique empirically derived 'weight'. The lowest possible weight is zero and the highest is 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in NIH GvHD grading score</measure>
    <time_frame>assessed at screening, after 1, 2, 3, 6, 9, 12, and after 13 months</time_frame>
    <description>NIH symptom-based lung score (score 0: no symptoms, score 1: shortness of breath with stairs, score 2: shortness of breath on flat ground, score 3: shortness of breath at rest or requiring oxygen)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) questionnaire</measure>
    <time_frame>assessed at screening, after 1, 2, 3, 6, 9, 12, and after 13 months</time_frame>
    <description>specific HSCT-patients validated self-report questionnaire using a 5 point Likert scale and covering 4 specific domains that include physical, social and family, emotional and functional well-being. Scoring produces a range from 0-148, the higher the score, the better the Quality of Life (QOL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>assessed at screening, after 1, 2, 3, 6, 9, 12, and after 13 months</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Bronchiolitis Obliterans Syndrome (BOS)</condition>
  <condition>Bronchiolitis Obliterans (BO)</condition>
  <arm_group>
    <arm_group_label>Nintedanib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nintedanib 150 mg Kps bid (oral)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nintedanib</intervention_name>
    <description>Nintedanib 150 mg Kps bid (oral); in order to manage adverse events, the dose of Nintedanib may be reduced from 150 mg twice daily to 100 mg twice daily</description>
    <arm_group_label>Nintedanib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Time interval from transplant &lt;/= 5 years at the time of inclusion&#xD;
&#xD;
          -  BOS as defined per the National Institute of Health (NIH) criteria:&#xD;
&#xD;
               1. FEV1/vital capacity &lt; 0.7 or the fifth percentile of predicted.&#xD;
&#xD;
               2. FEV1 &lt; 75% of predicted with ≥ 10% decline over less than 2 years.&#xD;
&#xD;
               3. Absence of infection in the respiratory tract, documented with investigations&#xD;
                  directed by clinical symptoms, such as chest radiographs, computed tomographic&#xD;
                  (CT) scans, or microbiologic cultures (sinus aspiration, upper respiratory tract&#xD;
                  viral screen, sputum culture, and broncho-alveolar lavage).&#xD;
&#xD;
               4. One of the 2 supporting features of BOS: 1. Evidence of air trapping by&#xD;
                  expiratory CT or small airway thickening or bronchiectasis by high-resolution&#xD;
                  chest CT, or 2. Evidence of air trapping by PFTs: residual volume &gt; 120% of&#xD;
                  predicted or residual volume/total lung capacity elevated outside the 90%&#xD;
                  confidence interval and prior or current diagnosis of cGvHD per NIH criteria or&#xD;
                  histologically proven BO&#xD;
&#xD;
          -  Diagnosis of BOS within 6 months before enrollment or prior diagnosis of BOS with an&#xD;
             absolute decline of the percentage of predicted forced expiratory volume in 1 second&#xD;
             (FEV1) by &gt;/= 10% within the past 12 months before inclusion&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Known intolerance to Nintedanib or any of its component&#xD;
&#xD;
          -  Pregnancy or nursing&#xD;
&#xD;
          -  Serum ALT &gt; 5 x upper limit of normal (ULN) unless explained entirely by liver GvHD or&#xD;
             total bilirubin &gt; 3x ULN unless explained entirely by liver GvHD&#xD;
&#xD;
          -  Any acute pulmonary infection with viruses, bacteria or fungi within four weeks before&#xD;
             study inclusion&#xD;
&#xD;
          -  Chronic oxygen therapy; non-invasive ventilation&#xD;
&#xD;
          -  Inability to give informed consent or to perform repeated pulmonary function tests&#xD;
             (PFT)&#xD;
&#xD;
          -  Life expectancy &lt; 1 year at the time of enrolment as suggested by the treating&#xD;
             physician&#xD;
&#xD;
          -  Hematologic malignancy in hematologic relapse&#xD;
&#xD;
          -  Symptomatic angina pectoris&#xD;
&#xD;
          -  Therapeutic anticoagulation (primary or secondary prophylactic platelet&#xD;
             anti-aggregation allowed)&#xD;
&#xD;
          -  Recent abdominal surgery or untreated gastric ulcer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katrin Hostettler Haack, PD Dr. med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinic of Respiratory Medicine, University Hospital Basel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katrin Hostettler Haack, PD Dr. med</last_name>
    <phone>+41 61 328 69 16</phone>
    <email>Katrin.Hostettler@usb.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sandra Kunze</last_name>
    <phone>+41 61 328 55 10</phone>
    <email>Sandra.Kunze@usb.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinic of Hematology, University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joerg Halter, PD Dr. med</last_name>
      <phone>+41 61 328 65 74</phone>
      <email>joerg.halter@usb.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinic of Respiratory Medicine, University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrin Hostettler Haack, PD Dr. med</last_name>
      <phone>+41 61 328 69 16</phone>
      <email>katrin.hostettler@usb.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
    <country>Germany</country>
  </removed_countries>
  <verification_date>May 2022</verification_date>
  <study_first_submitted>January 8, 2019</study_first_submitted>
  <study_first_submitted_qc>January 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2019</study_first_posted>
  <last_update_submitted>May 4, 2022</last_update_submitted>
  <last_update_submitted_qc>May 4, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>allogeneic hematopoietic cell transplantation.</keyword>
  <keyword>chronic graft-versus-host disease (cGvHD)</keyword>
  <keyword>Nintedanib</keyword>
  <keyword>fibrotic lung disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiolitis</mesh_term>
    <mesh_term>Bronchiolitis Obliterans</mesh_term>
    <mesh_term>Bronchiolitis Obliterans Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nintedanib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03805477
org study id: 2018-00837; me17Hostettler
nct id: NCT03805477
lead sponsor: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
This study investigates the safety and tolerability of Nintedanib in patients with
      bronchiolitis obliterans syndrome (BOS) following allogeneic hematopoietic cell
      transplantation. All study patients with BOS will be treated with the study drug Nintedanib
      (300 mg/day) as an add-on therapy to their basic immunosuppressive treatment over a 12-months
      treatment period.
Allogeneic hematopoietic stem cell transplantation (HCT) is an established treatment option
      for several malignant and non-malignant disorders. An important limitation of long-term
      survival after HCT is chronic graft-versus-host disease (cGvHD). The manifestation of cGvHD
      in the lungs, bronchiolitis obliterans (BO - if proven by lung biopsy) or bronchiolitis
      obliterans syndrome (BOS - clinical diagnosis), has a reported incidence between 5 and 20%.
      Despite different treatment approaches, prognosis of BO remains poor, with an overall 3-year
      mortality of up to 65%. Nintedanib is an orally available indolinone derivate that
      competitively binds to the vascular endothelial growth factor (VEGF) receptors, fibroblast
      growth factor (FGF) receptors, and platelet derived growth factor (PDGF) receptors. The
      anti-fibrotic activities of Nintedanib may impact the progressive course of fibrotic lung
      diseases like BO. This study investigates the safety and tolerability of Nintedanib in
      patients with bronchiolitis obliterans syndrome following allogeneic hematopoietic cell
      transplantation.
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: adverse event rate leading to interruption/ discontinuation of study treatment
time frame: from screening to month 12 after screening
description: adverse events of the following severity according to Common terminology criteria for adverse events(CTCAE): Diarrhoea ≥ grade 3; Nausea ≥ grade 3; Vomiting ≥ grade 3; Abdominal pain ≥ grade 3; Elevation of liver enzymes (AST, ALT) ≥ grade 2; Elevation of total bilirubin ≥ 2
measure: change of the percent of predicted forced expiratory volume in 1 second (FEV1)
time frame: Pulmonary function tests will be performed at screening, after 1, 2, 3, 6, 9, 12 and after 13 months
description: absolute change of the percent of predicted FEV1 by ≥10% from FEV1 before enrolment (eg, 50% to 40% predicted FEV1), confirmed by 2 pulmonary function tests (PFT) performed at least two weeks apart and after exclusion of infections and extra pulmonary causes
measure: change in forced vital capacity (FVC)
time frame: Pulmonary function tests will be performed at screening, after 1, 2, 3, 6, 9, 12 and after 13 months
description: volume of air that can forcibly be blown out after full inspiration, (measured in Liters)
measure: change in total lung capacity (TLC)
time frame: Pulmonary function tests will be performed at screening, after 1, 2, 3, 6, 9, 12 and after 13 months
description: the volume in the lungs at maximal Inflation (measured in liters)
measure: Change in diffusion capacity of the lung for carbon monoxide (DLCO)
time frame: Pulmonary function tests will be performed at screening, after 1, 2, 3, 6, 9, 12 and after 13 months
description: extent to which oxygen passes from the air sacs of the lungs into the blood (measured in "ml/min/kPa)
measure: Change in exhaled nitric oxide (eNO)
time frame: Pulmonary function tests will be performed at screening, after 1, 2, 3, 6, 9, 12 and after 13 months
description: Change in exhaled nitric oxide (eNO) (measured in parts per Billion)
measure: Nitrogen (N2)-washout
time frame: Pulmonary function tests will be performed at screening, after 1, 2, 3, 6, 9, 12 and after 13 months
description: The following describes a single-breath nitrogen test: A subject takes a breath of 100% oxygen and exhales through a one-way valve measuring nitrogen content and volume. A plot of the nitrogen concentration (as a % of total gas) vs. expired volume is obtained by increasing the nitrogen concentration from zero to the percentage of nitrogen in the alveoli. The nitrogen concentration is initially zero because the subject is exhaling the dead space oxygen they just breathed in (does not participate in alveolar exchange), and climbs as alveolar air mixes with the dead space air. The dead space can be determined from this curve by drawing a vertical line down the curve such that the areas below the curve (left of the line) and above the curve (right of the line) are equal
measure: changes in in 6 minutes walking distance (6-MWD)
time frame: 6-MWD will be performed at screening, after 6, after 12 months
description: standardized 6-minute walk test will be performed breathing room air and performed according to the guidelines of the American Thoracic Society. Significant drop of transcutaneous measured arterial oxygen Saturation (SaO2) is defined as a ΔSaO2 ≥ 4% or SaO2 < 90%. A significant change in walking distance will be Δ distance = 40 metre.
measure: cumulative steroid doses
time frame: assessed at screening, after 1, 2, 3, 6, 9, 12, and after 13 months
description: steroid doses per month (in mg)
measure: occurrence of GvHD in other organs
time frame: assessed at screening, after 1, 2, 3, 6, 9, 12, and after 13 months
description: occurrence of GvHD in other organs
measure: disease-free survival of underlying hematologic disease
time frame: assessed at screening, after 1, 2, 3, 6, 9, 12, and after 13 months
description: disease-free survival of underlying hematologic disease
measure: changes in St. George's Respiratory Questionnaire (SGRQ)
time frame: assessed at screening, after 1, 2, 3, 6, 9, 12, and after 13 months
description: The SGRQ is designed to measure health impairment in patients with asthma and chronic obstructive pulmonary disease (COPD); 3 component scores are calculated: symptoms; activity; impacts. Each questionnaire response has a unique empirically derived 'weight'. The lowest possible weight is zero and the highest is 100.
measure: changes in NIH GvHD grading score
time frame: assessed at screening, after 1, 2, 3, 6, 9, 12, and after 13 months
description: NIH symptom-based lung score (score 0: no symptoms, score 1: shortness of breath with stairs, score 2: shortness of breath on flat ground, score 3: shortness of breath at rest or requiring oxygen)
measure: changes in Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) questionnaire
time frame: assessed at screening, after 1, 2, 3, 6, 9, 12, and after 13 months
description: specific HSCT-patients validated self-report questionnaire using a 5 point Likert scale and covering 4 specific domains that include physical, social and family, emotional and functional well-being. Scoring produces a range from 0-148, the higher the score, the better the Quality of Life (QOL).
measure: overall survival
time frame: assessed at screening, after 1, 2, 3, 6, 9, 12, and after 13 months
description: overall survival
arm group label: Nintedanib
arm group type: Experimental
description: Nintedanib 150 mg Kps bid (oral)
intervention type: Drug
intervention name: Nintedanib
description: Nintedanib 150 mg Kps bid (oral); in order to manage adverse events, the dose of Nintedanib may be reduced from 150 mg twice daily to 100 mg twice daily
arm group label: Nintedanib
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Katrin Hostettler Haack, PD Dr. med
role: Principal Investigator
affiliation: Clinic of Respiratory Medicine, University Hospital Basel
last name: Katrin Hostettler Haack, PD Dr. med
phone: +41 61 328 69 16
email: Katrin.Hostettler@usb.ch
last name: Sandra Kunze
phone: +41 61 328 55 10
email: Sandra.Kunze@usb.ch
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
country: Switzerland
country: Austria
country: Germany
responsible party type: Sponsor
mesh term: Bronchiolitis
mesh term: Bronchiolitis Obliterans
mesh term: Bronchiolitis Obliterans Syndrome
mesh term: Syndrome
mesh term: Nintedanib